SIMILAR PATTERNS OF AMINO ACIDS FOR 1MUO_A_ADNA1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1d6s	O-ACETYLSERINE SULFHYDRYLASE (Salmonella enterica)	PF00291 (PALP)	6	LEU A 181 GLY A 178 VAL A 175 ALA A 201 LEU A 214 LEU A 240	None PLP A 501 (-3.6A) PLP A 501 ( 4.1A) None None None	0.99A	1muoA-1d6sA: undetectable	1muoA-1d6sA: 22.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1fot	CAMP-DEPENDENT PROTEIN KINASE TYPE 1 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	5	LEU A 93 GLY A 94 VAL A 101 ALA A 114 TYR A 166	None	0.43A	1muoA-1fotA: 23.2	1muoA-1fotA: 33.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1nxk	MAP KINASE-ACTIVATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 70 GLY A 71 VAL A 78 ALA A 91 LEU A 193	STU A 401 (-3.9A) STU A 401 (-3.6A) STU A 401 (-4.7A) STU A 401 (-3.4A) STU A 401 (-4.7A)	0.51A	1muoA-1nxkA: 7.8	1muoA-1nxkA: 28.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1py5	TGF-BETA RECEPTOR TYPE I (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	GLY A 212 VAL A 219 ALA A 230 LEU A 260 TYR A 282 LEU A 340	None PY1 A 700 ( 4.7A) PY1 A 700 (-3.5A) PY1 A 700 (-4.2A) PY1 A 700 (-4.6A) PY1 A 700 (-4.4A)	0.81A	1muoA-1py5A: 16.7	1muoA-1py5A: 26.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1q8y	SR PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 164 GLY A 165 VAL A 172 ALA A 185 LEU A 226 LEU A 301	ADP A 810 ( 4.3A) ADP A 810 (-3.3A) ADP A 810 (-4.1A) ADP A 810 (-3.3A) ADP A 810 (-4.4A) ADP A 810 (-4.7A)	0.82A	1muoA-1q8yA: 6.8	1muoA-1q8yA: 25.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 GLY A 617 VAL A 624 ALA A 642 TYR A 693 LEU A 818	None	0.67A	1muoA-1rjbA: 17.2	1muoA-1rjbA: 27.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 595 GLY A 596 VAL A 603 ALA A 621 TYR A 672 LEU A 799	STI A 3 ( 3.8A) None STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 ( 4.0A) STI A 3 (-4.4A)	0.76A	1muoA-1t46A: 7.7	1muoA-1t46A: 27.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 344 GLY A 345 VAL A 352 ALA A 367 ALA A 417 LEU A 468	STU A 100 (-3.8A) STU A 100 (-3.3A) STU A 100 (-4.8A) STU A 100 (-3.2A) STU A 100 (-3.7A) STU A 100 (-4.5A)	0.60A	1muoA-1u59A: 7.6	1muoA-1u59A: 29.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 15 GLY A 16 VAL A 23 ALA A 36 TYR A 86 LEU A 137	HYM A 400 (-4.2A) HYM A 400 ( 3.8A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-4.7A) HYM A 400 (-4.5A)	0.71A	1muoA-1zltA: 7.0	1muoA-1zltA: 29.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2buj	SERINE/THREONINE-PRO TEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 26 GLY A 27 VAL A 34 ALA A 47 LEU A 78 LEU A 155	STU A1301 (-4.2A) STU A1301 ( 3.8A) STU A1301 (-4.8A) STU A1301 (-3.6A) None STU A1301 ( 4.8A)	1.05A	1muoA-2bujA: 8.2	1muoA-2bujA: 26.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2cw6	HYDROXYMETHYLGLUTARY L-COA LYASE, MITOCHONDRIAL (Homo sapiens)	PF00682 (HMGL-like)	6	LEU A 263 GLY A 43 ALA A 261 LEU A 299 ALA A 302 LEU A 63	None	1.13A	1muoA-2cw6A: undetectable	1muoA-2cw6A: 22.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU X 17 GLY X 18 VAL X 25 ALA X 37 TYR X 84 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 3.7A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-4.6A) STU X 902 (-4.4A)	0.69A	1muoA-2dq7X: 8.4	1muoA-2dq7X: 26.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 GLY A 274 VAL A 281 ALA A 293 TYR A 340 LEU A 393	H8H A 534 (-3.8A) H8H A 534 ( 3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) H8H A 534 (-4.3A) H8H A 534 (-4.5A)	0.89A	1muoA-2h8hA: 7.8	1muoA-2h8hA: 22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hak	SERINE/THREONINE-PRO TEIN KINASE MARK1 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	5	VAL A 67 ALA A 80 TYR A 131 ALA A 132 LEU A 182	None	0.45A	1muoA-2hakA: 13.9	1muoA-2hakA: 29.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 55 GLY A 56 VAL A 63 ALA A 76 LEU A 108 LEU A 177	None	0.78A	1muoA-2hw6A: 24.3	1muoA-2hw6A: 30.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 251 GLY A 252 VAL A 259 ALA A 271 LEU A 371 TYR A 318	None None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.7A)	1.03A	1muoA-2og8A: 8.7	1muoA-2og8A: 28.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 588 GLY A 589 VAL A 596 ALA A 614 TYR A 665 LEU A 785	None	0.77A	1muoA-2ogvA: 17.0	1muoA-2ogvA: 27.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 344 GLY A 345 VAL A 352 ALA A 367 ALA A 417 LEU A 468	ANP A 615 (-4.4A) ANP A 615 ( 4.4A) ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 (-3.9A) ANP A 615 (-4.7A)	0.69A	1muoA-2ozoA: 9.6	1muoA-2ozoA: 17.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 GLY A 488 VAL A 495 ALA A 515 TYR A 566 ALA A 567 LEU A 633	None	0.78A	1muoA-2psqA: 7.9	1muoA-2psqA: 27.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2pwj	MITOCHONDRIAL PEROXIREDOXIN (Pisum sativum)	PF08534 (Redoxin)	6	GLY A 145 VAL A 142 ALA A 140 LEU A 122 ALA A 12 LEU A 120	None	1.29A	1muoA-2pwjA: undetectable	1muoA-2pwjA: 19.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 83 VAL A 90 ALA A 103 TYR A 155 LEU A 205	ANP A1480 ( 4.3A) None ANP A1480 ( 3.9A) ANP A1480 ( 4.9A) ANP A1480 ( 4.7A)	0.51A	1muoA-2v55A: 9.7	1muoA-2v55A: 27.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2w4o	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE IV (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 52 GLY A 53 VAL A 60 ALA A 73 LEU A 171	DKI A1338 (-3.8A) DKI A1338 (-3.3A) DKI A1338 (-4.2A) DKI A1338 ( 3.7A) DKI A1338 (-4.9A)	0.50A	1muoA-2w4oA: 24.4	1muoA-2w4oA: 31.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	SERINE/THREONINE-PRO TEIN KINASE 11 (Homo sapiens)	PF00069 (Pkinase)	6	LEU C 55 GLY C 56 VAL C 63 ALA C 76 TYR C 131 LEU C 183	ANP C 2 ( 4.4A) ANP C 2 (-3.3A) ANP C 2 (-4.2A) ANP C 2 (-3.4A) None None	0.80A	1muoA-2wtkC: 9.9	1muoA-2wtkC: 27.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2x4f	MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 112 GLY A 113 VAL A 120 ALA A 133 TYR A 182 LEU A 234	16X A1374 (-4.1A) 16X A1374 (-3.4A) 16X A1374 (-4.8A) 16X A1374 ( 3.8A) 16X A1374 (-4.1A) 16X A1374 ( 4.8A)	0.92A	1muoA-2x4fA: 11.2	1muoA-2x4fA: 28.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 GLY A 488 VAL A 495 ALA A 515 TYR A 566 ALA A 567 LEU A 633	M33 A1996 (-4.0A) M33 A1996 ( 3.8A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) M33 A1996 ( 4.7A) M33 A1996 (-3.8A) M33 A1996 (-4.5A)	0.69A	1muoA-3b2tA: 7.7	1muoA-3b2tA: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 484 VAL A 492 ALA A 512 TYR A 563 ALA A 564 LEU A 630	C4F A 1 ( 3.9A) None C4F A 1 (-3.3A) None C4F A 1 (-3.5A) C4F A 1 (-4.6A)	0.64A	1muoA-3c4fA: 8.1	1muoA-3c4fA: 28.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3eb0	PUTATIVE UNCHARACTERIZED PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	6	LEU A 15 GLY A 16 VAL A 23 ALA A 36 LEU A 173 TYR A 119	DRK A 384 (-3.8A) DRK A 384 ( 4.4A) None DRK A 384 (-3.5A) DRK A 384 (-4.4A) DRK A 384 (-4.4A)	1.39A	1muoA-3eb0A: 18.7	1muoA-3eb0A: 26.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3eb0	PUTATIVE UNCHARACTERIZED PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	6	LEU A 15 GLY A 16 VAL A 23 ALA A 36 TYR A 119 LEU A 173	DRK A 384 (-3.8A) DRK A 384 ( 4.4A) None DRK A 384 (-3.5A) DRK A 384 (-4.4A) DRK A 384 (-4.4A)	0.99A	1muoA-3eb0A: 18.7	1muoA-3eb0A: 26.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3fe3	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 3 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	GLY A 63 VAL A 70 ALA A 83 TYR A 134 ALA A 135 LEU A 185	None	0.70A	1muoA-3fe3A: 23.8	1muoA-3fe3A: 30.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 833 GLY A 834 VAL A 841 ALA A 859 TYR A 911 LEU A1029	8ST A2001 ( 4.7A) None 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.9A) None	0.56A	1muoA-3hngA: 18.2	1muoA-3hngA: 24.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	GLY A 60 VAL A 67 ALA A 80 TYR A 131 ALA A 132 LEU A 182	None	0.51A	1muoA-3iecA: 10.5	1muoA-3iecA: 29.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lm5	SERINE/THREONINE-PRO TEIN KINASE 17B (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 39 GLY A 40 VAL A 47 ALA A 60 TYR A 112 ALA A 113 LEU A 165	QUE A 1 ( 3.8A) None QUE A 1 ( 4.6A) QUE A 1 (-3.2A) QUE A 1 (-4.9A) QUE A 1 (-3.9A) None	0.71A	1muoA-3lm5A: 15.1	1muoA-3lm5A: 30.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	6	GLY A 211 VAL A 218 ALA A 229 LEU A 259 TYR A 281 LEU A 339	LDN A 1 ( 4.7A) LDN A 1 ( 4.8A) LDN A 1 (-3.6A) None LDN A 1 ( 4.8A) LDN A 1 (-4.5A)	0.85A	1muoA-3mdyA: 7.8	1muoA-3mdyA: 26.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mn3	CARBON CATABOLITE-DEREPRESS ING PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 61 VAL A 69 ALA A 82 TYR A 134 ALA A 135 LEU A 184	None	0.90A	1muoA-3mn3A: 22.9	1muoA-3mn3A: 32.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mtl	CELL DIVISION PROTEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 171 GLY A 172 VAL A 179 ALA A 192 TYR A 242 LEU A 293	FEF A 668 ( 3.8A) FEF A 668 ( 4.2A) FEF A 668 (-4.9A) FEF A 668 (-3.3A) FEF A 668 (-4.7A) FEF A 668 (-4.2A)	0.76A	1muoA-3mtlA: 10.4	1muoA-3mtlA: 27.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 49 GLY A 50 VAL A 57 ALA A 70 TYR A 122 LEU A 173	XFE A 351 (-4.2A) XFE A 351 ( 4.0A) XFE A 351 ( 4.5A) XFE A 351 (-3.2A) None XFE A 351 (-4.6A)	0.73A	1muoA-3mvjA: 9.8	1muoA-3mvjA: 28.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 209 VAL A 216 ALA A 227 LEU A 257 TYR A 279 LEU A 337	None LDN A 600 (-4.5A) LDN A 600 (-3.2A) None LDN A 600 (-4.7A) LDN A 600 (-4.6A)	0.97A	1muoA-3my0A: 16.3	1muoA-3my0A: 28.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 88 GLY A 89 VAL A 96 ALA A 109 TYR A 161 ALA A 162 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 ( 4.3A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) None JOZ A 361 (-3.8A) None	0.61A	1muoA-3nuuA: 10.9	1muoA-3nuuA: 33.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 423 GLY A 424 VAL A 431 ALA A 443 TYR A 491 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 ( 4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-3.2A) PP2 A 1 ( 4.9A) PP2 A 1 (-4.6A)	0.70A	1muoA-3sxsA: 8.8	1muoA-3sxsA: 24.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 GLY A 485 VAL A 492 ALA A 512 TYR A 563 ALA A 564 LEU A 630	07J A 1 ( 4.3A) 07J A 1 ( 4.9A) 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.7A) 07J A 1 (-3.8A) 07J A 1 ( 4.4A)	0.52A	1muoA-3tt0A: 7.8	1muoA-3tt0A: 26.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	LEU A 295 GLY A 296 VAL A 303 ALA A 315 LEU A 347 TYR A 365 LEU A 423	None	0.98A	1muoA-3ulzA: 18.8	1muoA-3ulzA: 28.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 139 GLY A 140 VAL A 147 ALA A 160 LEU A 194 TYR A 212 ALA A 213 LEU A 263	N13 A 501 (-3.7A) None N13 A 501 ( 4.7A) N13 A 501 ( 4.1A) N13 A 501 (-4.9A) N13 A 501 (-4.4A) N13 A 501 (-3.7A) N13 A 501 (-4.5A)	0.74A	1muoA-3w18A: 16.6	1muoA-3w18A: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	5	LEU A 75 GLY A 76 VAL A 83 ALA A 96 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 3.7A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) ANP A 401 (-4.8A)	0.52A	1muoA-3wigA: 19.5	1muoA-3wigA: 28.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1951 GLY A1952 VAL A1959 ALA A1978 LEU A2010 LEU A2086	VGH A3000 ( 4.4A) None None VGH A3000 (-3.4A) VGH A3000 (-4.8A) VGH A3000 (-4.3A)	1.06A	1muoA-3zbfA: 18.8	1muoA-3zbfA: 26.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 83 GLY A 84 VAL A 91 ALA A 104 LEU A 138 TYR A 156 ALA A 157 LEU A 207	VX6 A 500 (-3.8A) VX6 A 500 ( 4.1A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.4A) None VX6 A 500 (-4.2A) VX6 A 500 (-3.7A) VX6 A 500 (-4.6A)	0.47A	1muoA-4af3A: 9.1	1muoA-4af3A: 66.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 560 GLY A 561 VAL A 568 ALA A 586 TYR A 635 LEU A 699	LTI A1839 ( 4.2A) LTI A1839 ( 4.3A) None LTI A1839 (-3.3A) LTI A1839 (-4.7A) LTI A1839 (-4.2A)	0.88A	1muoA-4at3A: 8.8	1muoA-4at3A: 27.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	6	GLY A 215 VAL A 222 ALA A 233 LEU A 263 TYR A 285 LEU A 343	None TAK A1507 (-4.7A) TAK A1507 (-3.3A) FLC A1503 ( 4.5A) TAK A1507 ( 4.6A) TAK A1507 (-4.7A)	0.88A	1muoA-4c02A: 7.8	1muoA-4c02A: 26.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	7	LEU A 246 GLY A 247 VAL A 254 ALA A 267 TYR A 320 ALA A 321 LEU A 371	None	0.44A	1muoA-4c0tA: 10.8	1muoA-4c0tA: 13.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 GLY A 617 VAL A 624 ALA A 653 LEU A 773 TYR A 703	None None DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-4.5A) DI1 A1000 (-4.0A)	0.98A	1muoA-4ckrA: 7.6	1muoA-4ckrA: 25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 663 VAL A 671 ALA A 684 TYR A 739 ALA A 740 LEU A 789	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) None AGS A1985 (-3.9A) AGS A1985 (-4.8A)	0.53A	1muoA-4crsA: 20.6	1muoA-4crsA: 29.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4eqm	PROTEIN KINASE (Staphylococcus aureus)	PF00069 (Pkinase)	6	LEU A 16 GLY A 17 VAL A 24 ALA A 37 TYR A 89 LEU A 140	ANP A 300 (-4.7A) ANP A 300 ( 4.4A) ANP A 300 ( 4.7A) ANP A 300 ( 3.8A) ANP A 300 (-4.3A) ANP A 300 (-4.7A)	0.64A	1muoA-4eqmA: 12.5	1muoA-4eqmA: 30.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 377 GLY A 378 VAL A 385 ALA A 400 ALA A 451 LEU A 501	0SB A 701 ( 3.9A) 0SB A 701 (-3.6A) 0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 (-4.0A) 0SB A 701 (-4.4A)	0.94A	1muoA-4f4pA: 7.6	1muoA-4f4pA: 26.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 377 GLY A 378 VAL A 385 ALA A 400 ALA A 451 LEU A 501	ANP A 701 ( 4.6A) ANP A 701 ( 4.0A) ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 (-4.1A) ANP A 701 (-4.5A)	0.73A	1muoA-4fl3A: 8.9	1muoA-4fl3A: 17.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	LEU A 855 GLY A 856 VAL A 863 ALA A 880 TYR A 931 LEU A 983	IZA A2001 (-3.7A) IZA A2001 ( 4.9A) None IZA A2001 (-3.4A) None IZA A2001 ( 4.7A)	0.74A	1muoA-4gl9A: 7.4	1muoA-4gl9A: 27.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 156 GLY A 157 VAL A 164 ALA A 177 TYR A 229 ALA A 230	0XZ A 501 ( 4.1A) GOL A 505 ( 3.4A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) 0XZ A 501 ( 4.9A) 0XZ A 501 (-3.7A)	0.59A	1muoA-4gv1A: 9.6	1muoA-4gv1A: 31.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 828 GLY A 829 VAL A 836 ALA A 853 TYR A 904 LEU A 956	19S A1201 (-3.9A) 19S A1201 (-3.7A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 (-4.7A) 19S A1201 (-4.5A)	0.65A	1muoA-4hviA: 18.3	1muoA-4hviA: 26.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	LEU A 132 GLY A 133 VAL A 140 ALA A 156 ALA A 208 LEU A 259	None	0.63A	1muoA-4hzsA: 16.5	1muoA-4hzsA: 26.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 132 GLY A 133 VAL A 140 ALA A 156 ALA A 208 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 ( 4.2A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.8A) 1G0 A 401 (-4.6A)	0.63A	1muoA-4id7A: 7.8	1muoA-4id7A: 26.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jrn	RHOPTRY KINASE FAMILY PROTEIN (Toxoplasma gondii)	PF14531 (Kinase-like)	6	LEU A 258 GLY A 259 VAL A 266 ALA A 279 ALA A 359 LEU A 416	ANP A 601 ( 4.6A) ANP A 601 (-3.4A) ANP A 601 (-4.1A) ANP A 601 ( 3.9A) ANP A 601 (-3.5A) ANP A 601 ( 4.9A)	0.86A	1muoA-4jrnA: 6.0	1muoA-4jrnA: 26.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 GLY A 274 VAL A 281 ALA A 293 TYR A 340 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 ( 4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) 0J9 A 601 (-4.5A)	0.84A	1muoA-4k11A: 7.7	1muoA-4k11A: 21.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 478 GLY A 479 VAL A 486 ALA A 506 TYR A 557 ALA A 558 LEU A 624	ACP A 801 (-3.8A) ACP A 801 (-3.4A) ACP A 801 (-4.2A) ACP A 801 (-3.3A) None ACP A 801 (-3.7A) ACP A 801 (-4.4A)	0.73A	1muoA-4k33A: 18.3	1muoA-4k33A: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4l52	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	GLY A 43 VAL A 50 ALA A 61 TYR A 106 ALA A 107 LEU A 163	1UL A 501 ( 4.1A) 1UL A 501 ( 4.9A) 1UL A 501 (-3.1A) 1UL A 501 (-4.1A) 1UL A 501 (-3.6A) 1UL A 501 (-4.3A)	0.75A	1muoA-4l52A: 18.7	1muoA-4l52A: 28.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 33 GLY A 34 VAL A 41 ALA A 54 TYR A 101 LEU A 153	GOL A 404 ( 3.6A) None GOL A 404 (-4.5A) GOL A 404 ( 3.1A) GOL A 404 ( 4.9A) GOL A 403 ( 4.4A)	0.78A	1muoA-4lg4A: 21.7	1muoA-4lg4A: 28.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	LEU A 273 GLY A 274 VAL A 281 ALA A 293 TYR A 340 LEU A 393	VGG A 601 (-3.2A) VGG A 601 ( 3.8A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) VGG A 601 ( 4.0A) VGG A 601 (-4.5A)	0.80A	1muoA-4lggA: 7.0	1muoA-4lggA: 23.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mvf	CALCIUM-DEPENDENT PROTEIN KINASE 2 (Plasmodium falciparum)	PF00069 (Pkinase) PF13499 (EF-hand_7)	5	LEU A 78 GLY A 79 VAL A 86 ALA A 99 LEU A 199	STU A 601 ( 4.0A) STU A 601 (-3.6A) STU A 601 (-4.8A) STU A 601 (-3.3A) STU A 601 (-4.7A)	0.49A	1muoA-4mvfA: 6.0	1muoA-4mvfA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 GLY A 904 VAL A 911 ALA A 928 TYR A 980 LEU A1030	2TT A1202 (-3.5A) 2TT A1202 ( 4.2A) 2TT A1202 (-4.5A) 2TT A1202 ( 3.9A) 2TT A1202 (-4.6A) 2TT A1202 (-4.4A)	0.75A	1muoA-4oliA: 7.8	1muoA-4oliA: 21.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 627 GLY A 628 VAL A 635 ALA A 648 TYR A 703 LEU A 753	None	0.73A	1muoA-4otdA: 9.3	1muoA-4otdA: 29.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 386 GLY A 387 VAL A 394 ALA A 407 TYR A 460 LEU A 511	PZW A 801 (-3.9A) PZW A 801 ( 3.8A) PZW A 801 (-4.6A) PZW A 801 (-3.5A) None PZW A 801 (-4.8A)	0.70A	1muoA-4q9zA: 9.4	1muoA-4q9zA: 31.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 GLY A 617 VAL A 624 ALA A 642 TYR A 693 LEU A 818	P30 A1001 (-3.8A) None None P30 A1001 (-3.4A) P30 A1001 (-4.1A) P30 A1001 (-4.6A)	0.68A	1muoA-4rt7A: 8.1	1muoA-4rt7A: 26.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	LEU A 14 GLY A 15 VAL A 22 ALA A 35 LEU A 136 TYR A 83	ACP A1264 ( 4.5A) ACP A1264 ( 4.2A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) ACP A1264 ( 4.8A) ACP A1264 ( 4.5A)	1.18A	1muoA-4ueuA: 12.1	1muoA-4ueuA: 28.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	6	LEU A 14 GLY A 15 VAL A 22 ALA A 35 TYR A 83 LEU A 136	ACP A1264 ( 4.5A) ACP A1264 ( 4.2A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) ACP A1264 ( 4.5A) ACP A1264 ( 4.8A)	0.93A	1muoA-4ueuA: 12.1	1muoA-4ueuA: 28.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	6	LEU A 104 GLY A 105 VAL A 112 ALA A 125 TYR A 177 LEU A 228	ATP A 501 ( 4.3A) ATP A 501 (-3.5A) ATP A 501 (-4.0A) ATP A 501 (-3.4A) None ATP A 501 (-4.5A)	0.70A	1muoA-4wb7A: 10.2	1muoA-4wb7A: 27.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 473 GLY A 474 VAL A 481 ALA A 501 ALA A 553 LEU A 619	40M A1002 ( 4.6A) None 40M A1002 ( 4.5A) 40M A1002 ( 4.1A) 40M A1002 (-3.7A) 40M A1002 (-4.5A)	0.61A	1muoA-4xcuA: 8.4	1muoA-4xcuA: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xgn	3-HYDROXYACYL-COA DEHYDROGENASE (Burkholderia thailandensis)	PF00106 (adh_short)	6	GLY A 114 VAL A 58 ALA A 64 LEU A 9 ALA A 122 LEU A 80	None NAD A 300 (-3.6A) None None None None	1.19A	1muoA-4xgnA: undetectable	1muoA-4xgnA: 23.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 408 GLY A 409 VAL A 416 ALA A 428 TYR A 476 LEU A 528	None	0.99A	1muoA-4xi2A: 18.3	1muoA-4xi2A: 23.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 GLY A 617 VAL A 624 ALA A 642 TYR A 693 LEU A 818	P30 A1001 (-4.0A) None P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 ( 4.4A) P30 A1001 (-4.3A)	0.81A	1muoA-4xufA: 23.5	1muoA-4xufA: 27.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	LEU A 408 GLY A 409 VAL A 416 ALA A 428 TYR A 476 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 3.5A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) 746 A 702 (-4.4A) 746 A 702 (-4.4A)	0.71A	1muoA-4y93A: 11.6	1muoA-4y93A: 22.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ynz	SERINE/THREONINE-PRO TEIN KINASE BRSK2 (Mus musculus)	PF00069 (Pkinase)	6	LEU A 26 GLY A 27 VAL A 34 ALA A 47 LEU A 80 LEU A 149	None	0.70A	1muoA-4ynzA: 15.9	1muoA-4ynzA: 29.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 GLY A 485 VAL A 492 ALA A 512 TYR A 563 ALA A 564 LEU A 630	38O A1769 (-3.2A) 38O A1769 ( 4.7A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 (-4.2A) 38O A1769 (-3.9A) 38O A1769 (-4.6A)	0.67A	1muoA-5a46A: 7.8	1muoA-5a46A: 26.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5es1	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	6	GLY A 63 VAL A 70 ALA A 83 TYR A 134 ALA A 135 LEU A 185	5RC A4000 ( 4.3A) 5RC A4000 (-4.6A) 5RC A4000 (-3.6A) 5RC A4000 (-4.5A) 5RC A4000 (-3.7A) None	0.57A	1muoA-5es1A: 25.4	1muoA-5es1A: 30.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	7	LEU A 99 GLY A 100 VAL A 107 ALA A 120 LEU A 154 ALA A 173 LEU A 223	5U5 A 401 (-3.8A) 5U5 A 401 (-3.8A) 5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-4.8A) 5U5 A 401 (-3.9A) 5U5 A 401 (-4.7A)	0.51A	1muoA-5eykA: 28.0	1muoA-5eykA: 67.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 GLY A 904 VAL A 911 ALA A 928 TYR A 980 LEU A1030	5U3 A1200 (-3.8A) 5U3 A1200 ( 3.7A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) 5U3 A1200 (-4.5A) 5U3 A1200 (-4.4A)	0.63A	1muoA-5f1zA: 7.7	1muoA-5f1zA: 27.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 730 GLY A 731 VAL A 738 ALA A 756 TYR A 806 ALA A 807 LEU A 881	PP1 A2012 (-4.6A) PP1 A2012 ( 3.9A) PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) None PP1 A2012 ( 3.5A) PP1 A2012 (-4.6A)	0.80A	1muoA-5fm2A: 8.5	1muoA-5fm2A: 24.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 599 GLY A 600 VAL A 607 ALA A 625 TYR A 676 LEU A 825	748 A1001 (-3.8A) None 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-4.3A)	0.70A	1muoA-5grnA: 18.0	1muoA-5grnA: 25.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5idn	CYCLIN-DEPENDENT KINASE 8 (Homo sapiens)	PF00069 (Pkinase)	6	GLY A 28 VAL A 35 ALA A 50 TYR A 99 ALA A 100 LEU A 158	6A7 A 401 (-3.6A) 6A7 A 401 ( 4.5A) 6A7 A 401 (-3.3A) 6A7 A 401 (-4.9A) 6A7 A 401 (-3.7A) 6A7 A 401 (-4.8A)	0.72A	1muoA-5idnA: 9.6	1muoA-5idnA: 26.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5iso	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (Homo sapiens)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	6	LEU A 22 GLY A 23 VAL A 30 ALA A 43 TYR A 95 LEU A 146	STU A 601 (-4.1A) STU A 601 (-3.4A) STU A 601 (-4.8A) STU A 601 (-3.3A) STU A 601 (-4.3A) STU A 601 (-4.5A)	0.57A	1muoA-5isoA: 10.9	1muoA-5isoA: 19.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5m09	SERINE/THREONINE-PRO TEIN KINASE PKNI (Mycobacterium tuberculosis)	PF00069 (Pkinase)	6	LEU A 18 GLY A 19 VAL A 26 ALA A 39 LEU A 73 TYR A 91	None	0.73A	1muoA-5m09A: 6.0	1muoA-5m09A: 25.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tvt	MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (Homo sapiens)	no annotation	5	GLY A 18 VAL A 25 ALA A 38 TYR A 88 LEU A 139	7LV A 401 ( 3.9A) 7LV A 401 ( 4.6A) 7LV A 401 (-3.4A) 7LV A 401 (-4.6A) 7LV A 401 (-4.9A)	0.49A	1muoA-5tvtA: 11.3	1muoA-5tvtA: 28.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	5	GLY A 99 VAL A 106 ALA A 119 TYR A 171 LEU A 221	None	0.51A	1muoA-5u7qA: 10.0	1muoA-5u7qA: 30.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	6	LEU A 24 VAL A 32 ALA A 45 LEU A 79 TYR A 97 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-4.9A) None 9WS A 401 (-4.6A)	0.82A	1muoA-5w5jA: 8.2	1muoA-5w5jA: 28.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wnm	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 4 (Mus musculus)	no annotation	6	GLY A 29 VAL A 36 ALA A 49 LEU A 82 TYR A 98 LEU A 150	VX6 A 402 ( 4.2A) VX6 A 402 (-4.6A) VX6 A 402 (-3.2A) VX6 A 402 ( 4.8A) VX6 A 402 (-4.3A) VX6 A 402 (-4.4A)	0.65A	1muoA-5wnmA: 8.4	1muoA-5wnmA: 15.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	7	LEU A 891 GLY A 892 VAL A 899 ALA A 917 LEU A 947 TYR A 965 LEU A1017	ANP A1201 (-4.1A) ANP A1201 ( 3.8A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-4.7A) ANP A1201 (-4.4A) ANP A1201 (-4.7A)	0.74A	1muoA-5wnoA: 9.3	1muoA-5wnoA: 18.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	6	LEU A 891 GLY A 892 VAL A 899 ALA A 917 LEU A1017 TYR A 965	ANP A1201 (-4.1A) ANP A1201 ( 3.8A) ANP A1201 (-4.4A) ANP A1201 (-3.3A) ANP A1201 (-4.7A) ANP A1201 (-4.4A)	0.94A	1muoA-5wnoA: 9.3	1muoA-5wnoA: 18.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	6	GLY A 76 VAL A 83 ALA A 95 TYR A 143 ALA A 144 LEU A 206	ANP A1000 ( 3.8A) ANP A1000 (-4.1A) ANP A1000 (-3.2A) ANP A1000 (-4.3A) ANP A1000 (-3.5A) ANP A1000 (-4.5A)	0.76A	1muoA-5xd6A: 19.7	1muoA-5xd6A: 13.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	6	LEU A 33 GLY A 34 VAL A 41 ALA A 54 TYR A 101 LEU A 153	ANP A 501 ( 3.8A) ANP A 501 ( 3.9A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 ( 4.2A) ANP A 501 (-4.6A)	0.74A	1muoA-6ao5A: 21.1	1muoA-6ao5A: 26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bx6	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (Homo sapiens)	no annotation	6	LEU A 22 GLY A 23 VAL A 30 ALA A 43 TYR A 95 LEU A 146	EDJ A 301 (-3.9A) EDJ A 301 (-3.4A) None EDJ A 301 (-3.4A) EDJ A 301 ( 4.8A) EDJ A 301 ( 4.5A)	0.67A	1muoA-6bx6A: 20.7	1muoA-6bx6A: 15.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c62	BIURET HYDROLASE (Pseudomonas sp. ADP)	no annotation	6	LEU A 187 GLY A 186 VAL A 412 LEU A 248 TYR A 223 ALA A 220	None	1.49A	1muoA-6c62A: undetectable	1muoA-6c62A: 16.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9d	SERINE/THREONINE-PRO TEIN KINASE MARK1,SERINE/THREONI NE-PROTEIN KINASE MARK1 (Homo sapiens)	no annotation	6	GLY A 67 VAL A 74 ALA A 87 TYR A 138 ALA A 139 LEU A 189	None	0.66A	1muoA-6c9dA: 10.4	1muoA-6c9dA: 12.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	6	LEU A 197 GLY A 198 VAL A 205 ALA A 217 LEU A 248 LEU A 319	FKY A9001 (-4.1A) FKY A9001 ( 4.0A) FKY A9001 ( 4.6A) FKY A9001 (-3.3A) FKY A9001 (-4.2A) FKY A9001 ( 4.9A)	0.78A	1muoA-6cz4A: 11.6	1muoA-6cz4A: 14.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	7	LEU A 730 GLY A 731 VAL A 738 ALA A 756 TYR A 806 ALA A 807 LEU A 881	ADN A1104 ( 4.0A) ADN A1104 ( 3.9A) ADN A1104 (-4.4A) ADN A1104 (-3.4A) ADN A1104 ( 4.1A) ADN A1104 (-3.6A) ADN A1104 (-4.3A)	0.73A	1muoA-6fekA: 7.7	1muoA-6fekA: 15.22

[["1MUO_A_ADNA1_1","1d6s","Salmonella enterica","O-ACETYLSERINE SULFHYDRYLASE","PF00291(PALP)",6,"LEU A 181;GLY A 178;VAL A 175;ALA A 201;LEU A 214;LEU A 240","None;PLP A 501 (-3.6A);PLP A 501 ( 4.1A);None;None;None","0.99A","1muoA-1d6sA:undetectable","1muoA-1d6sA:22.66"],["1MUO_A_ADNA1_1","1fot","Saccharomyces cerevisiae","CAMP-DEPENDENT PROTEIN KINASE TYPE 1","PF00069(Pkinase)",5,"LEU A  93;GLY A  94;VAL A 101;ALA A 114;TYR A 166","None","0.43A","1muoA-1fotA:23.2","1muoA-1fotA:33.83"],["1MUO_A_ADNA1_1","1nxk","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 2","PF00069(Pkinase)",5,"LEU A  70;GLY A  71;VAL A  78;ALA A  91;LEU A 193","STU A 401 (-3.9A);STU A 401 (-3.6A);STU A 401 (-4.7A);STU A 401 (-3.4A);STU A 401 (-4.7A)","0.51A","1muoA-1nxkA:7.8","1muoA-1nxkA:28.33"],["1MUO_A_ADNA1_1","1py5","Homo sapiens","TGF-BETA RECEPTOR TYPE I","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"GLY A 212;VAL A 219;ALA A 230;LEU A 260;TYR A 282;LEU A 340","None;PY1 A 700 ( 4.7A);PY1 A 700 (-3.5A);PY1 A 700 (-4.2A);PY1 A 700 (-4.6A);PY1 A 700 (-4.4A)","0.81A","1muoA-1py5A:16.7","1muoA-1py5A:26.51"],["1MUO_A_ADNA1_1","1q8y","Saccharomyces cerevisiae","SR PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A 164;GLY A 165;VAL A 172;ALA A 185;LEU A 226;LEU A 301","ADP A 810 ( 4.3A);ADP A 810 (-3.3A);ADP A 810 (-4.1A);ADP A 810 (-3.3A);ADP A 810 (-4.4A);ADP A 810 (-4.7A)","0.82A","1muoA-1q8yA:6.8","1muoA-1q8yA:25.19"],["1MUO_A_ADNA1_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;TYR A 693;LEU A 818","None","0.67A","1muoA-1rjbA:17.2","1muoA-1rjbA:27.40"],["1MUO_A_ADNA1_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",6,"LEU A 595;GLY A 596;VAL A 603;ALA A 621;TYR A 672;LEU A 799","STI A   3 ( 3.8A);None;STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 ( 4.0A);STI A   3 (-4.4A)","0.76A","1muoA-1t46A:7.7","1muoA-1t46A:27.05"],["1MUO_A_ADNA1_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",6,"LEU A 344;GLY A 345;VAL A 352;ALA A 367;ALA A 417;LEU A 468","STU A 100 (-3.8A);STU A 100 (-3.3A);STU A 100 (-4.8A);STU A 100 (-3.2A);STU A 100 (-3.7A);STU A 100 (-4.5A)","0.60A","1muoA-1u59A:7.6","1muoA-1u59A:29.21"],["1MUO_A_ADNA1_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",6,"LEU A  15;GLY A  16;VAL A  23;ALA A  36;TYR A  86;LEU A 137","HYM A 400 (-4.2A);HYM A 400 ( 3.8A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-4.7A);HYM A 400 (-4.5A)","0.71A","1muoA-1zltA:7.0","1muoA-1zltA:29.01"],["1MUO_A_ADNA1_1","2buj","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 16","PF00069(Pkinase)",6,"LEU A  26;GLY A  27;VAL A  34;ALA A  47;LEU A  78;LEU A 155","STU A1301 (-4.2A);STU A1301 ( 3.8A);STU A1301 (-4.8A);STU A1301 (-3.6A);None;STU A1301 ( 4.8A)","1.05A","1muoA-2bujA:8.2","1muoA-2bujA:26.59"],["1MUO_A_ADNA1_1","2cw6","Homo sapiens","HYDROXYMETHYLGLUTARYL-COA LYASE, MITOCHONDRIAL","PF00682(HMGL-like)",6,"LEU A 263;GLY A  43;ALA A 261;LEU A 299;ALA A 302;LEU A  63","None","1.13A","1muoA-2cw6A:undetectable","1muoA-2cw6A:22.99"],["1MUO_A_ADNA1_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"LEU X  17;GLY X  18;VAL X  25;ALA X  37;TYR X  84;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 3.7A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-4.6A);STU X 902 (-4.4A)","0.69A","1muoA-2dq7X:8.4","1muoA-2dq7X:26.50"],["1MUO_A_ADNA1_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;GLY A 274;VAL A 281;ALA A 293;TYR A 340;LEU A 393","H8H A 534 (-3.8A);H8H A 534 ( 3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);H8H A 534 (-4.3A);H8H A 534 (-4.5A)","0.89A","1muoA-2h8hA:7.8","1muoA-2h8hA:22.39"],["1MUO_A_ADNA1_1","2hak","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1","PF00069(Pkinase);PF00627(UBA)",5,"VAL A  67;ALA A  80;TYR A 131;ALA A 132;LEU A 182","None","0.45A","1muoA-2hakA:13.9","1muoA-2hakA:29.41"],["1MUO_A_ADNA1_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  55;GLY A  56;VAL A  63;ALA A  76;LEU A 108;LEU A 177","None","0.78A","1muoA-2hw6A:24.3","1muoA-2hw6A:30.54"],["1MUO_A_ADNA1_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",6,"LEU A 251;GLY A 252;VAL A 259;ALA A 271;LEU A 371;TYR A 318","None;None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 4.3A);1N8 A 501 ( 3.7A)","1.03A","1muoA-2og8A:8.7","1muoA-2og8A:28.72"],["1MUO_A_ADNA1_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"LEU A 588;GLY A 589;VAL A 596;ALA A 614;TYR A 665;LEU A 785","None","0.77A","1muoA-2ogvA:17.0","1muoA-2ogvA:27.59"],["1MUO_A_ADNA1_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 344;GLY A 345;VAL A 352;ALA A 367;ALA A 417;LEU A 468","ANP A 615 (-4.4A);ANP A 615 ( 4.4A);ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 (-3.9A);ANP A 615 (-4.7A)","0.69A","1muoA-2ozoA:9.6","1muoA-2ozoA:17.41"],["1MUO_A_ADNA1_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;GLY A 488;VAL A 495;ALA A 515;TYR A 566;ALA A 567;LEU A 633","None","0.78A","1muoA-2psqA:7.9","1muoA-2psqA:27.01"],["1MUO_A_ADNA1_1","2pwj","Pisum sativum","MITOCHONDRIAL PEROXIREDOXIN","PF08534(Redoxin)",6,"GLY A 145;VAL A 142;ALA A 140;LEU A 122;ALA A  12;LEU A 120","None","1.29A","1muoA-2pwjA:undetectable","1muoA-2pwjA:19.66"],["1MUO_A_ADNA1_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",5,"GLY A  83;VAL A  90;ALA A 103;TYR A 155;LEU A 205","ANP A1480 ( 4.3A);None;ANP A1480 ( 3.9A);ANP A1480 ( 4.9A);ANP A1480 ( 4.7A)","0.51A","1muoA-2v55A:9.7","1muoA-2v55A:27.23"],["1MUO_A_ADNA1_1","2w4o","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE IV","PF00069(Pkinase)",5,"LEU A  52;GLY A  53;VAL A  60;ALA A  73;LEU A 171","DKI A1338 (-3.8A);DKI A1338 (-3.3A);DKI A1338 (-4.2A);DKI A1338 ( 3.7A);DKI A1338 (-4.9A)","0.50A","1muoA-2w4oA:24.4","1muoA-2w4oA:31.73"],["1MUO_A_ADNA1_1","2wtk","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 11","PF00069(Pkinase)",6,"LEU C  55;GLY C  56;VAL C  63;ALA C  76;TYR C 131;LEU C 183","ANP C   2 ( 4.4A);ANP C   2 (-3.3A);ANP C   2 (-4.2A);ANP C   2 (-3.4A);None;None","0.80A","1muoA-2wtkC:9.9","1muoA-2wtkC:27.41"],["1MUO_A_ADNA1_1","2x4f","Homo sapiens","MYOSIN LIGHT CHAIN KINASE FAMILY MEMBER 4","PF00069(Pkinase)",6,"LEU A 112;GLY A 113;VAL A 120;ALA A 133;TYR A 182;LEU A 234","16X A1374 (-4.1A);16X A1374 (-3.4A);16X A1374 (-4.8A);16X A1374 ( 3.8A);16X A1374 (-4.1A);16X A1374 ( 4.8A)","0.92A","1muoA-2x4fA:11.2","1muoA-2x4fA:28.22"],["1MUO_A_ADNA1_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;GLY A 488;VAL A 495;ALA A 515;TYR A 566;ALA A 567;LEU A 633","M33 A1996 (-4.0A);M33 A1996 ( 3.8A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);M33 A1996 ( 4.7A);M33 A1996 (-3.8A);M33 A1996 (-4.5A)","0.69A","1muoA-3b2tA:7.7","1muoA-3b2tA:27.27"],["1MUO_A_ADNA1_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"LEU A 484;VAL A 492;ALA A 512;TYR A 563;ALA A 564;LEU A 630","C4F A   1 ( 3.9A);None;C4F A   1 (-3.3A);None;C4F A   1 (-3.5A);C4F A   1 (-4.6A)","0.64A","1muoA-3c4fA:8.1","1muoA-3c4fA:28.53"],["1MUO_A_ADNA1_1","3eb0","Cryptosporidium parvum","PUTATIVE UNCHARACTERIZED PROTEIN","PF00069(Pkinase)",6,"LEU A  15;GLY A  16;VAL A  23;ALA A  36;LEU A 173;TYR A 119","DRK A 384 (-3.8A);DRK A 384 ( 4.4A);None;DRK A 384 (-3.5A);DRK A 384 (-4.4A);DRK A 384 (-4.4A)","1.39A","1muoA-3eb0A:18.7","1muoA-3eb0A:26.28"],["1MUO_A_ADNA1_1","3eb0","Cryptosporidium parvum","PUTATIVE UNCHARACTERIZED PROTEIN","PF00069(Pkinase)",6,"LEU A  15;GLY A  16;VAL A  23;ALA A  36;TYR A 119;LEU A 173","DRK A 384 (-3.8A);DRK A 384 ( 4.4A);None;DRK A 384 (-3.5A);DRK A 384 (-4.4A);DRK A 384 (-4.4A)","0.99A","1muoA-3eb0A:18.7","1muoA-3eb0A:26.28"],["1MUO_A_ADNA1_1","3fe3","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 3","PF00069(Pkinase);PF00627(UBA)",6,"GLY A  63;VAL A  70;ALA A  83;TYR A 134;ALA A 135;LEU A 185","None","0.70A","1muoA-3fe3A:23.8","1muoA-3fe3A:30.29"],["1MUO_A_ADNA1_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"LEU A 833;GLY A 834;VAL A 841;ALA A 859;TYR A 911;LEU A1029","8ST A2001 ( 4.7A);None;8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.9A);None","0.56A","1muoA-3hngA:18.2","1muoA-3hngA:24.15"],["1MUO_A_ADNA1_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",6,"GLY A  60;VAL A  67;ALA A  80;TYR A 131;ALA A 132;LEU A 182","None","0.51A","1muoA-3iecA:10.5","1muoA-3iecA:29.12"],["1MUO_A_ADNA1_1","3lm5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 17B","PF00069(Pkinase)",7,"LEU A  39;GLY A  40;VAL A  47;ALA A  60;TYR A 112;ALA A 113;LEU A 165","QUE A   1 ( 3.8A);None;QUE A   1 ( 4.6A);QUE A   1 (-3.2A);QUE A   1 (-4.9A);QUE A   1 (-3.9A);None","0.71A","1muoA-3lm5A:15.1","1muoA-3lm5A:30.06"],["1MUO_A_ADNA1_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",6,"GLY A 211;VAL A 218;ALA A 229;LEU A 259;TYR A 281;LEU A 339","LDN A   1 ( 4.7A);LDN A   1 ( 4.8A);LDN A   1 (-3.6A);None;LDN A   1 ( 4.8A);LDN A   1 (-4.5A)","0.85A","1muoA-3mdyA:7.8","1muoA-3mdyA:26.83"],["1MUO_A_ADNA1_1","3mn3","Saccharomyces cerevisiae","CARBON CATABOLITE-DEREPRESSING PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  61;VAL A  69;ALA A  82;TYR A 134;ALA A 135;LEU A 184","None","0.90A","1muoA-3mn3A:22.9","1muoA-3mn3A:32.65"],["1MUO_A_ADNA1_1","3mtl","Homo sapiens","CELL DIVISION PROTEIN KINASE 16","PF00069(Pkinase)",6,"LEU A 171;GLY A 172;VAL A 179;ALA A 192;TYR A 242;LEU A 293","FEF A 668 ( 3.8A);FEF A 668 ( 4.2A);FEF A 668 (-4.9A);FEF A 668 (-3.3A);FEF A 668 (-4.7A);FEF A 668 (-4.2A)","0.76A","1muoA-3mtlA:10.4","1muoA-3mtlA:27.48"],["1MUO_A_ADNA1_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",6,"LEU A  49;GLY A  50;VAL A  57;ALA A  70;TYR A 122;LEU A 173","XFE A 351 (-4.2A);XFE A 351 ( 4.0A);XFE A 351 ( 4.5A);XFE A 351 (-3.2A);None;XFE A 351 (-4.6A)","0.73A","1muoA-3mvjA:9.8","1muoA-3mvjA:28.46"],["1MUO_A_ADNA1_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",6,"GLY A 209;VAL A 216;ALA A 227;LEU A 257;TYR A 279;LEU A 337","None;LDN A 600 (-4.5A);LDN A 600 (-3.2A);None;LDN A 600 (-4.7A);LDN A 600 (-4.6A)","0.97A","1muoA-3my0A:16.3","1muoA-3my0A:28.78"],["1MUO_A_ADNA1_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",7,"LEU A  88;GLY A  89;VAL A  96;ALA A 109;TYR A 161;ALA A 162;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 ( 4.3A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);None;JOZ A 361 (-3.8A);None","0.61A","1muoA-3nuuA:10.9","1muoA-3nuuA:33.77"],["1MUO_A_ADNA1_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"LEU A 423;GLY A 424;VAL A 431;ALA A 443;TYR A 491;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 ( 4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-3.2A);PP2 A   1 ( 4.9A);PP2 A   1 (-4.6A)","0.70A","1muoA-3sxsA:8.8","1muoA-3sxsA:24.16"],["1MUO_A_ADNA1_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;GLY A 485;VAL A 492;ALA A 512;TYR A 563;ALA A 564;LEU A 630","07J A   1 ( 4.3A);07J A   1 ( 4.9A);07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.7A);07J A   1 (-3.8A);07J A   1 ( 4.4A)","0.52A","1muoA-3tt0A:7.8","1muoA-3tt0A:26.61"],["1MUO_A_ADNA1_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",7,"LEU A 295;GLY A 296;VAL A 303;ALA A 315;LEU A 347;TYR A 365;LEU A 423","None","0.98A","1muoA-3ulzA:18.8","1muoA-3ulzA:28.48"],["1MUO_A_ADNA1_1","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",8,"LEU A 139;GLY A 140;VAL A 147;ALA A 160;LEU A 194;TYR A 212;ALA A 213;LEU A 263","N13 A 501 (-3.7A);None;N13 A 501 ( 4.7A);N13 A 501 ( 4.1A);N13 A 501 (-4.9A);N13 A 501 (-4.4A);N13 A 501 (-3.7A);N13 A 501 (-4.5A)","0.74A","1muoA-3w18A:16.6","1muoA-3w18A:100.00"],["1MUO_A_ADNA1_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",5,"LEU A  75;GLY A  76;VAL A  83;ALA A  96;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 3.7A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);ANP A 401 (-4.8A)","0.52A","1muoA-3wigA:19.5","1muoA-3wigA:28.10"],["1MUO_A_ADNA1_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",6,"LEU A1951;GLY A1952;VAL A1959;ALA A1978;LEU A2010;LEU A2086","VGH A3000 ( 4.4A);None;None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);VGH A3000 (-4.3A)","1.06A","1muoA-3zbfA:18.8","1muoA-3zbfA:26.10"],["1MUO_A_ADNA1_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",8,"LEU A  83;GLY A  84;VAL A  91;ALA A 104;LEU A 138;TYR A 156;ALA A 157;LEU A 207","VX6 A 500 (-3.8A);VX6 A 500 ( 4.1A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.4A);None;VX6 A 500 (-4.2A);VX6 A 500 (-3.7A);VX6 A 500 (-4.6A)","0.47A","1muoA-4af3A:9.1","1muoA-4af3A:66.67"],["1MUO_A_ADNA1_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 560;GLY A 561;VAL A 568;ALA A 586;TYR A 635;LEU A 699","LTI A1839 ( 4.2A);LTI A1839 ( 4.3A);None;LTI A1839 (-3.3A);LTI A1839 (-4.7A);LTI A1839 (-4.2A)","0.88A","1muoA-4at3A:8.8","1muoA-4at3A:27.84"],["1MUO_A_ADNA1_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",6,"GLY A 215;VAL A 222;ALA A 233;LEU A 263;TYR A 285;LEU A 343","None;TAK A1507 (-4.7A);TAK A1507 (-3.3A);FLC A1503 ( 4.5A);TAK A1507 ( 4.6A);TAK A1507 (-4.7A)","0.88A","1muoA-4c02A:7.8","1muoA-4c02A:26.14"],["1MUO_A_ADNA1_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A 246;GLY A 247;VAL A 254;ALA A 267;TYR A 320;ALA A 321;LEU A 371","None","0.44A","1muoA-4c0tA:10.8","1muoA-4c0tA:13.57"],["1MUO_A_ADNA1_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"LEU A 616;GLY A 617;VAL A 624;ALA A 653;LEU A 773;TYR A 703","None;None;DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-4.5A);DI1 A1000 (-4.0A)","0.98A","1muoA-4ckrA:7.6","1muoA-4ckrA:25.94"],["1MUO_A_ADNA1_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 663;VAL A 671;ALA A 684;TYR A 739;ALA A 740;LEU A 789","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;AGS A1985 (-3.9A);AGS A1985 (-4.8A)","0.53A","1muoA-4crsA:20.6","1muoA-4crsA:29.15"],["1MUO_A_ADNA1_1","4eqm","Staphylococcus aureus","PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  16;GLY A  17;VAL A  24;ALA A  37;TYR A  89;LEU A 140","ANP A 300 (-4.7A);ANP A 300 ( 4.4A);ANP A 300 ( 4.7A);ANP A 300 ( 3.8A);ANP A 300 (-4.3A);ANP A 300 (-4.7A)","0.64A","1muoA-4eqmA:12.5","1muoA-4eqmA:30.84"],["1MUO_A_ADNA1_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"LEU A 377;GLY A 378;VAL A 385;ALA A 400;ALA A 451;LEU A 501","0SB A 701 ( 3.9A);0SB A 701 (-3.6A);0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 (-4.0A);0SB A 701 (-4.4A)","0.94A","1muoA-4f4pA:7.6","1muoA-4f4pA:26.42"],["1MUO_A_ADNA1_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 377;GLY A 378;VAL A 385;ALA A 400;ALA A 451;LEU A 501","ANP A 701 ( 4.6A);ANP A 701 ( 4.0A);ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 (-4.1A);ANP A 701 (-4.5A)","0.73A","1muoA-4fl3A:8.9","1muoA-4fl3A:17.60"],["1MUO_A_ADNA1_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"LEU A 855;GLY A 856;VAL A 863;ALA A 880;TYR A 931;LEU A 983","IZA A2001 (-3.7A);IZA A2001 ( 4.9A);None;IZA A2001 (-3.4A);None;IZA A2001 ( 4.7A)","0.74A","1muoA-4gl9A:7.4","1muoA-4gl9A:27.64"],["1MUO_A_ADNA1_1","4gv1","Homo sapiens","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 156;GLY A 157;VAL A 164;ALA A 177;TYR A 229;ALA A 230","0XZ A 501 ( 4.1A);GOL A 505 ( 3.4A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);0XZ A 501 ( 4.9A);0XZ A 501 (-3.7A)","0.59A","1muoA-4gv1A:9.6","1muoA-4gv1A:31.05"],["1MUO_A_ADNA1_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"LEU A 828;GLY A 829;VAL A 836;ALA A 853;TYR A 904;LEU A 956","19S A1201 (-3.9A);19S A1201 (-3.7A);19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 (-4.7A);19S A1201 (-4.5A)","0.65A","1muoA-4hviA:18.3","1muoA-4hviA:26.82"],["1MUO_A_ADNA1_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"LEU A 132;GLY A 133;VAL A 140;ALA A 156;ALA A 208;LEU A 259","None","0.63A","1muoA-4hzsA:16.5","1muoA-4hzsA:26.32"],["1MUO_A_ADNA1_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"LEU A 132;GLY A 133;VAL A 140;ALA A 156;ALA A 208;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 ( 4.2A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.8A);1G0 A 401 (-4.6A)","0.63A","1muoA-4id7A:7.8","1muoA-4id7A:26.69"],["1MUO_A_ADNA1_1","4jrn","Toxoplasma gondii","RHOPTRY KINASE FAMILY PROTEIN","PF14531(Kinase-like)",6,"LEU A 258;GLY A 259;VAL A 266;ALA A 279;ALA A 359;LEU A 416","ANP A 601 ( 4.6A);ANP A 601 (-3.4A);ANP A 601 (-4.1A);ANP A 601 ( 3.9A);ANP A 601 (-3.5A);ANP A 601 ( 4.9A)","0.86A","1muoA-4jrnA:6.0","1muoA-4jrnA:26.34"],["1MUO_A_ADNA1_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;GLY A 274;VAL A 281;ALA A 293;TYR A 340;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 ( 4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);0J9 A 601 (-4.5A)","0.84A","1muoA-4k11A:7.7","1muoA-4k11A:21.72"],["1MUO_A_ADNA1_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"LEU A 478;GLY A 479;VAL A 486;ALA A 506;TYR A 557;ALA A 558;LEU A 624","ACP A 801 (-3.8A);ACP A 801 (-3.4A);ACP A 801 (-4.2A);ACP A 801 (-3.3A);None;ACP A 801 (-3.7A);ACP A 801 (-4.4A)","0.73A","1muoA-4k33A:18.3","1muoA-4k33A:28.45"],["1MUO_A_ADNA1_1","4l52","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA","PF07714(Pkinase_Tyr)",6,"GLY A  43;VAL A  50;ALA A  61;TYR A 106;ALA A 107;LEU A 163","1UL A 501 ( 4.1A);1UL A 501 ( 4.9A);1UL A 501 (-3.1A);1UL A 501 (-4.1A);1UL A 501 (-3.6A);1UL A 501 (-4.3A)","0.75A","1muoA-4l52A:18.7","1muoA-4l52A:28.61"],["1MUO_A_ADNA1_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"LEU A  33;GLY A  34;VAL A  41;ALA A  54;TYR A 101;LEU A 153","GOL A 404 ( 3.6A);None;GOL A 404 (-4.5A);GOL A 404 ( 3.1A);GOL A 404 ( 4.9A);GOL A 403 ( 4.4A)","0.78A","1muoA-4lg4A:21.7","1muoA-4lg4A:28.79"],["1MUO_A_ADNA1_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",6,"LEU A 273;GLY A 274;VAL A 281;ALA A 293;TYR A 340;LEU A 393","VGG A 601 (-3.2A);VGG A 601 ( 3.8A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);VGG A 601 ( 4.0A);VGG A 601 (-4.5A)","0.80A","1muoA-4lggA:7.0","1muoA-4lggA:23.53"],["1MUO_A_ADNA1_1","4mvf","Plasmodium falciparum","CALCIUM-DEPENDENT PROTEIN KINASE 2","PF00069(Pkinase);PF13499(EF-hand_7)",5,"LEU A  78;GLY A  79;VAL A  86;ALA A  99;LEU A 199","STU A 601 ( 4.0A);STU A 601 (-3.6A);STU A 601 (-4.8A);STU A 601 (-3.3A);STU A 601 (-4.7A)","0.49A","1muoA-4mvfA:6.0","1muoA-4mvfA:25.98"],["1MUO_A_ADNA1_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;GLY A 904;VAL A 911;ALA A 928;TYR A 980;LEU A1030","2TT A1202 (-3.5A);2TT A1202 ( 4.2A);2TT A1202 (-4.5A);2TT A1202 ( 3.9A);2TT A1202 (-4.6A);2TT A1202 (-4.4A)","0.75A","1muoA-4oliA:7.8","1muoA-4oliA:21.21"],["1MUO_A_ADNA1_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 627;GLY A 628;VAL A 635;ALA A 648;TYR A 703;LEU A 753","None","0.73A","1muoA-4otdA:9.3","1muoA-4otdA:29.02"],["1MUO_A_ADNA1_1","4q9z","Homo sapiens","HUMAN PROTEIN KINASE C THETA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 386;GLY A 387;VAL A 394;ALA A 407;TYR A 460;LEU A 511","PZW A 801 (-3.9A);PZW A 801 ( 3.8A);PZW A 801 (-4.6A);PZW A 801 (-3.5A);None;PZW A 801 (-4.8A)","0.70A","1muoA-4q9zA:9.4","1muoA-4q9zA:31.71"],["1MUO_A_ADNA1_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;TYR A 693;LEU A 818","P30 A1001 (-3.8A);None;None;P30 A1001 (-3.4A);P30 A1001 (-4.1A);P30 A1001 (-4.6A)","0.68A","1muoA-4rt7A:8.1","1muoA-4rt7A:26.12"],["1MUO_A_ADNA1_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"LEU A  14;GLY A  15;VAL A  22;ALA A  35;LEU A 136;TYR A  83","ACP A1264 ( 4.5A);ACP A1264 ( 4.2A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);ACP A1264 ( 4.8A);ACP A1264 ( 4.5A)","1.18A","1muoA-4ueuA:12.1","1muoA-4ueuA:28.08"],["1MUO_A_ADNA1_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",6,"LEU A  14;GLY A  15;VAL A  22;ALA A  35;TYR A  83;LEU A 136","ACP A1264 ( 4.5A);ACP A1264 ( 4.2A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);ACP A1264 ( 4.5A);ACP A1264 ( 4.8A)","0.93A","1muoA-4ueuA:12.1","1muoA-4ueuA:28.08"],["1MUO_A_ADNA1_1","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",6,"LEU A 104;GLY A 105;VAL A 112;ALA A 125;TYR A 177;LEU A 228","ATP A 501 ( 4.3A);ATP A 501 (-3.5A);ATP A 501 (-4.0A);ATP A 501 (-3.4A);None;ATP A 501 (-4.5A)","0.70A","1muoA-4wb7A:10.2","1muoA-4wb7A:27.07"],["1MUO_A_ADNA1_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"LEU A 473;GLY A 474;VAL A 481;ALA A 501;ALA A 553;LEU A 619","40M A1002 ( 4.6A);None;40M A1002 ( 4.5A);40M A1002 ( 4.1A);40M A1002 (-3.7A);40M A1002 (-4.5A)","0.61A","1muoA-4xcuA:8.4","1muoA-4xcuA:27.78"],["1MUO_A_ADNA1_1","4xgn","Burkholderia thailandensis","3-HYDROXYACYL-COA DEHYDROGENASE","PF00106(adh_short)",6,"GLY A 114;VAL A  58;ALA A  64;LEU A   9;ALA A 122;LEU A  80","None;NAD A 300 (-3.6A);None;None;None;None","1.19A","1muoA-4xgnA:undetectable","1muoA-4xgnA:23.82"],["1MUO_A_ADNA1_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 408;GLY A 409;VAL A 416;ALA A 428;TYR A 476;LEU A 528","None","0.99A","1muoA-4xi2A:18.3","1muoA-4xi2A:23.01"],["1MUO_A_ADNA1_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;GLY A 617;VAL A 624;ALA A 642;TYR A 693;LEU A 818","P30 A1001 (-4.0A);None;P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 ( 4.4A);P30 A1001 (-4.3A)","0.81A","1muoA-4xufA:23.5","1muoA-4xufA:27.08"],["1MUO_A_ADNA1_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"LEU A 408;GLY A 409;VAL A 416;ALA A 428;TYR A 476;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 3.5A);746 A 702 ( 4.3A);746 A 702 (-2.4A);746 A 702 (-4.4A);746 A 702 (-4.4A)","0.71A","1muoA-4y93A:11.6","1muoA-4y93A:22.29"],["1MUO_A_ADNA1_1","4ynz","Mus musculus","SERINE\/THREONINE-PROTEIN KINASE BRSK2","PF00069(Pkinase)",6,"LEU A  26;GLY A  27;VAL A  34;ALA A  47;LEU A  80;LEU A 149","None","0.70A","1muoA-4ynzA:15.9","1muoA-4ynzA:29.67"],["1MUO_A_ADNA1_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",7,"LEU A 484;GLY A 485;VAL A 492;ALA A 512;TYR A 563;ALA A 564;LEU A 630","38O A1769 (-3.2A);38O A1769 ( 4.7A);38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 (-4.2A);38O A1769 (-3.9A);38O A1769 (-4.6A)","0.67A","1muoA-5a46A:7.8","1muoA-5a46A:26.34"],["1MUO_A_ADNA1_1","5es1","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 4","PF00069(Pkinase);PF00627(UBA)",6,"GLY A  63;VAL A  70;ALA A  83;TYR A 134;ALA A 135;LEU A 185","5RC A4000 ( 4.3A);5RC A4000 (-4.6A);5RC A4000 (-3.6A);5RC A4000 (-4.5A);5RC A4000 (-3.7A);None","0.57A","1muoA-5es1A:25.4","1muoA-5es1A:30.46"],["1MUO_A_ADNA1_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",7,"LEU A  99;GLY A 100;VAL A 107;ALA A 120;LEU A 154;ALA A 173;LEU A 223","5U5 A 401 (-3.8A);5U5 A 401 (-3.8A);5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-4.8A);5U5 A 401 (-3.9A);5U5 A 401 (-4.7A)","0.51A","1muoA-5eykA:28.0","1muoA-5eykA:67.38"],["1MUO_A_ADNA1_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;GLY A 904;VAL A 911;ALA A 928;TYR A 980;LEU A1030","5U3 A1200 (-3.8A);5U3 A1200 ( 3.7A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);5U3 A1200 (-4.5A);5U3 A1200 (-4.4A)","0.63A","1muoA-5f1zA:7.7","1muoA-5f1zA:27.61"],["1MUO_A_ADNA1_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"LEU A 730;GLY A 731;VAL A 738;ALA A 756;TYR A 806;ALA A 807;LEU A 881","PP1 A2012 (-4.6A);PP1 A2012 ( 3.9A);PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);None;PP1 A2012 ( 3.5A);PP1 A2012 (-4.6A)","0.80A","1muoA-5fm2A:8.5","1muoA-5fm2A:24.40"],["1MUO_A_ADNA1_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"LEU A 599;GLY A 600;VAL A 607;ALA A 625;TYR A 676;LEU A 825","748 A1001 (-3.8A);None;748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-4.3A)","0.70A","1muoA-5grnA:18.0","1muoA-5grnA:25.35"],["1MUO_A_ADNA1_1","5idn","Homo sapiens","CYCLIN-DEPENDENT KINASE 8","PF00069(Pkinase)",6,"GLY A  28;VAL A  35;ALA A  50;TYR A  99;ALA A 100;LEU A 158","6A7 A 401 (-3.6A);6A7 A 401 ( 4.5A);6A7 A 401 (-3.3A);6A7 A 401 (-4.9A);6A7 A 401 (-3.7A);6A7 A 401 (-4.8A)","0.72A","1muoA-5idnA:9.6","1muoA-5idnA:26.48"],["1MUO_A_ADNA1_1","5iso","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2","PF00069(Pkinase);PF16579(AdenylateSensor)",6,"LEU A  22;GLY A  23;VAL A  30;ALA A  43;TYR A  95;LEU A 146","STU A 601 (-4.1A);STU A 601 (-3.4A);STU A 601 (-4.8A);STU A 601 (-3.3A);STU A 601 (-4.3A);STU A 601 (-4.5A)","0.57A","1muoA-5isoA:10.9","1muoA-5isoA:19.61"],["1MUO_A_ADNA1_1","5m09","Mycobacterium tuberculosis","SERINE\/THREONINE-PROTEIN KINASE PKNI","PF00069(Pkinase)",6,"LEU A  18;GLY A  19;VAL A  26;ALA A  39;LEU A  73;TYR A  91","None","0.73A","1muoA-5m09A:6.0","1muoA-5m09A:25.62"],["1MUO_A_ADNA1_1","5tvt","Homo sapiens","MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE","no annotation",5,"GLY A  18;VAL A  25;ALA A  38;TYR A  88;LEU A 139","7LV A 401 ( 3.9A);7LV A 401 ( 4.6A);7LV A 401 (-3.4A);7LV A 401 (-4.6A);7LV A 401 (-4.9A)","0.49A","1muoA-5tvtA:11.3","1muoA-5tvtA:28.37"],["1MUO_A_ADNA1_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",5,"GLY A  99;VAL A 106;ALA A 119;TYR A 171;LEU A 221","None","0.51A","1muoA-5u7qA:10.0","1muoA-5u7qA:30.03"],["1MUO_A_ADNA1_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",6,"LEU A  24;VAL A  32;ALA A  45;LEU A  79;TYR A  97;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-4.9A);None;9WS A 401 (-4.6A)","0.82A","1muoA-5w5jA:8.2","1muoA-5w5jA:28.09"],["1MUO_A_ADNA1_1","5wnm","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 4","no annotation",6,"GLY A  29;VAL A  36;ALA A  49;LEU A  82;TYR A  98;LEU A 150","VX6 A 402 ( 4.2A);VX6 A 402 (-4.6A);VX6 A 402 (-3.2A);VX6 A 402 ( 4.8A);VX6 A 402 (-4.3A);VX6 A 402 (-4.4A)","0.65A","1muoA-5wnmA:8.4","1muoA-5wnmA:15.15"],["1MUO_A_ADNA1_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",7,"LEU A 891;GLY A 892;VAL A 899;ALA A 917;LEU A 947;TYR A 965;LEU A1017","ANP A1201 (-4.1A);ANP A1201 ( 3.8A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-4.7A);ANP A1201 (-4.4A);ANP A1201 (-4.7A)","0.74A","1muoA-5wnoA:9.3","1muoA-5wnoA:18.99"],["1MUO_A_ADNA1_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",6,"LEU A 891;GLY A 892;VAL A 899;ALA A 917;LEU A1017;TYR A 965","ANP A1201 (-4.1A);ANP A1201 ( 3.8A);ANP A1201 (-4.4A);ANP A1201 (-3.3A);ANP A1201 (-4.7A);ANP A1201 (-4.4A)","0.94A","1muoA-5wnoA:9.3","1muoA-5wnoA:18.99"],["1MUO_A_ADNA1_1","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",6,"GLY A  76;VAL A  83;ALA A  95;TYR A 143;ALA A 144;LEU A 206","ANP A1000 ( 3.8A);ANP A1000 (-4.1A);ANP A1000 (-3.2A);ANP A1000 (-4.3A);ANP A1000 (-3.5A);ANP A1000 (-4.5A)","0.76A","1muoA-5xd6A:19.7","1muoA-5xd6A:13.65"],["1MUO_A_ADNA1_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",6,"LEU A  33;GLY A  34;VAL A  41;ALA A  54;TYR A 101;LEU A 153","ANP A 501 ( 3.8A);ANP A 501 ( 3.9A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 ( 4.2A);ANP A 501 (-4.6A)","0.74A","1muoA-6ao5A:21.1","1muoA-6ao5A:26.36"],["1MUO_A_ADNA1_1","6bx6","Homo sapiens","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2","no annotation",6,"LEU A  22;GLY A  23;VAL A  30;ALA A  43;TYR A  95;LEU A 146","EDJ A 301 (-3.9A);EDJ A 301 (-3.4A);None;EDJ A 301 (-3.4A);EDJ A 301 ( 4.8A);EDJ A 301 ( 4.5A)","0.67A","1muoA-6bx6A:20.7","1muoA-6bx6A:15.52"],["1MUO_A_ADNA1_1","6c62","Pseudomonas sp. ADP","BIURET HYDROLASE","no annotation",6,"LEU A 187;GLY A 186;VAL A 412;LEU A 248;TYR A 223;ALA A 220","None","1.49A","1muoA-6c62A:undetectable","1muoA-6c62A:16.00"],["1MUO_A_ADNA1_1","6c9d","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1,SERINE\/THREONINE-PROTEIN KINASE MARK1","no annotation",6,"GLY A  67;VAL A  74;ALA A  87;TYR A 138;ALA A 139;LEU A 189","None","0.66A","1muoA-6c9dA:10.4","1muoA-6c9dA:12.73"],["1MUO_A_ADNA1_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",6,"LEU A 197;GLY A 198;VAL A 205;ALA A 217;LEU A 248;LEU A 319","FKY A9001 (-4.1A);FKY A9001 ( 4.0A);FKY A9001 ( 4.6A);FKY A9001 (-3.3A);FKY A9001 (-4.2A);FKY A9001 ( 4.9A)","0.78A","1muoA-6cz4A:11.6","1muoA-6cz4A:14.80"],["1MUO_A_ADNA1_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",7,"LEU A 730;GLY A 731;VAL A 738;ALA A 756;TYR A 806;ALA A 807;LEU A 881","ADN A1104 ( 4.0A);ADN A1104 ( 3.9A);ADN A1104 (-4.4A);ADN A1104 (-3.4A);ADN A1104 ( 4.1A);ADN A1104 (-3.6A);ADN A1104 (-4.3A)","0.73A","1muoA-6fekA:7.7","1muoA-6fekA:15.22"]]